Lancet Oncol: Prolonged treatment with letrozole for 5 years can significantly improve the survival prognosis of menopausal early breast cancer patients

Aromatase inhibitors are currently a class of endocrine therapy drugs widely used clinically in postmenopausal breast cancer
.

In the case of previous use of aromatase inhibitors, the benefits of extending the treatment time of aromatase inhibitors for more than 5 years are still controversial

Breast cancer

This study aims to compare the aromatase inhibitor letrozole prolonged therapy (5 years) and letrozole standard therapy (2-3 years) for postmenopausal breast cancer that has been treated with tamoxifen for 2-3 years Benefit and safety in patients
.

Compare the effectiveness of aromatase inhibitor letrozole prolonged therapy (5 years) versus standard letrozole therapy (2-3 years) in postmenopausal breast cancer patients who have been treated with tamoxifen for 2-3 years Comparison with safety aromatase inhibitor letrozole prolonged therapy (5 years) vs.
letrozole standard therapy (2-3 years) for postmenopausal breast cancer patients who have been treated with tamoxifen for 2-3 years Benefits and safety in

This is a multi-center, open-label, randomized phase 3 trial conducted in 69 hospitals in Italy, recruiting menopausal, histologically confirmed stage I-III, surgically treatable aggressive hormone receptor positive Patients with breast cancer who require prior tamoxifen adjuvant treatment for two years and no more than 3 years and 3 months, no signs of recurrence, and ECOG performance status ≤ 2 points
.

The test patients were randomly (1:1) divided into the control group (letrozole treatment for 2-3 years) and the extended group (letrozole treatment for 5 years), and oral letrozole 2.

Disease-free survival rate and overall survival rate of the two groups

Disease-free survival rate and overall survival rate of the two groups

From August 1st, 2005 to 19th 24th, 2010, a total of 2056 patients were recruited and randomly divided into the control group (n=1030) and the extended group (n=1026)
.

After a median follow-up of 11.

The 12-year disease-free survival rates of the control group and the extended group were 62% (95% CI 57-66) and 67% (62-71) (hazard ratio 0.

Adverse events

Adverse events

The most common grade 3 or 4 adverse events were arthralgia (control group vs prolonged group: 2.
2% vs 3.
0%) and myalgia (0.
7% vs 0.
9%)
.

There were 3 cases (0.

All in all, letrozole extended treatment for 5 years can significantly improve the disease-free survival rate of postmenopausal breast cancer patients who have received tamoxifen treatment for 2-3 years compared with 2-3 years of letrozole standard treatment
.

Tamoxifen endocrine therapy for 2-3 years, followed by trazole therapy for 5 years of sequential therapy, may be used as one of the best standard endocrine treatments for menopausal hormone receptor-positive breast cancer patients

Letrozole prolonged treatment for 5 years can significantly improve the disease-free survival rate of postmenopausal breast cancer patients who have previously received tamoxifen for 2-3 years compared to standard letrozole treatment for 2-3 years.

Original source:

Lucia Del Mastro, et al.

Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial in this message